Metraipolis › archive › dc_6e36933db21b
Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 — Europe PMC PPR:PPR180354
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR180354
- DOI
- 10.1101/2020.06.25.20140384
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-08T08:04:59.903Z
- SHA-256 of the archived text
140582859dbc6d523b4b57045feffe050bab11cddf95905a4aa9a56921ad7584- Stable URL of this page
https://metraipolis.com/documento/dc_6e36933db21b
How to cite
Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 — Europe PMC PPR:PPR180354 — Europe PMC, https://europepmc.org/article/PPR/PPR180354 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_6e36933db21b (Metraipolis archive dc_6e36933db21b, sha256 140582859dbc6d523b4b57045feffe050bab11cddf95905a4aa9a56921ad7584)
BibTeX
@misc{dc6e36933db21b,
title = {Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 — Europe PMC PPR:PPR180354},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR180354},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_6e36933db21b; sha256 140582859dbc6d523b4b57045feffe050bab11cddf95905a4aa9a56921ad7584},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR180354. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Importance: Reported cases of SARS-CoV-2 infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected. Objective: To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the United States. Design: Serologic testing of convenience samples using residual sera obtained for routine clinical testing by two commercial laboratory companies. Setting: Connecticut (CT), south Florida (FL), Missouri (MO), New York City metro region (NYC), Utah (UT), and Washington State’s (WA) Puget Sound region. Participants: Persons of all ages with serum collected during intervals from March 23 through May 3, 2020. Exposure: SARS-CoV-2 virus infection. Main outcomes and measures: We estimated the presence of antibodies to SARS-CoV-2 spike protein using an ELISA assay. We standardized estimates to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). We estimated the number of infections in each site by extrapolating seroprevalence to site populations. We compared estimated infections to number of reported COVID-19 cases as of last specimen collection date. Results: We tested sera from 11,933 persons. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein ranged from 1.13% (95% confidence interval [CI] 0.70-1.94) in WA to 6.93% (95% CI 5.02-8.92) in NYC (collected March 23-April 1). For sites with later collection dates, estimates ranged from 1.85% (95% CI 1.00-3.23, collected April 6-10) for FL to 4.94% (95% CI 3.61-6.52) for CT (April 26-May 3). The estimated number of infections ranged from 6 to 24 times the number of reported cases in each site. Conclusions and relevance: Our seroprevalence estimates suggest that for five of six U.S. sites, from late March to early May 2020, >10 times more SARS-CoV-2 infections occurred than the number of reported cases. Seroprevalence and under-ascertainment varied by site and specimen collection period. Most specimens from each site had no evidence of antibody to SARS-CoV-2. Tracking population seroprevalence serially, in a variety of specific geographic sites, will inform models of transmission dynamics and guide future community-wide public health measures. Key findings: Question: What proportion of persons in six U.S. sites had detectable antibodies to SARS-CoV-2, March 23-May 3, 2020? Findings: We tested 11,933 residual clinical specimens. We estimate that from 1.1% of persons in the Puget Sound to 6.9% in New York City (collected March 23-April 1) had detectable antibodies. Estimates ranged from 1.9% in south Florida to 4.9% in Connecticut with specimens collected during intervals from April 6-May 3. Six to 24 times more infections were estimated per site with seroprevalence than with case report data. Meaning: For most sites, evidence suggests >10 times more SARS-CoV-2 infections occurred than reported cases. Most persons in each site likely had no detectable SARS-CoV-2 antibodies. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: medRxiv, 2020 (prima pubblicazione 2020-06-26). Identificativi: DOI 10.1101/2020.06.25.20140384. Pagina: https://europepmc.org/article/PPR/PPR180354 — https://doi.org/10.1101/2020.06.25.20140384. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-08T08:00:45.322Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.